{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:23:04Z","timestamp":1792628584920,"version":"4.5.0"},"reference-count":19,"publisher":"SLACK, Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n            <jats:title>Background and Objective:<\/jats:title>\n            <jats:p>We report our initial experience with intravitreal bevacizumab-bvzr, a bevacizumab biosimilar approved by the US Food and Drug Administration in 2019 and recently introduced by our institution for off-label ophthalmologic use in children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>This was an Institutional Review Board-approved single-institution retrospective case series of pediatric patients 21 years or younger who received at least one intravitreal injection of biosimilar bevacizumab-bvzr.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twelve eyes of 9 patients were identified as having received intravitreal bevacizumab-bvzr, with a total of 13 injections performed. Indications for injection included retinopathy of prematurity (7\/13), choroidal neovascularization (3\/13), retinal vein occlusion (2\/13), and Coats disease (1\/13). Following injection of bevacizumab-bvzr, all patients experienced a positive clinical response. No occurrences of postinjection inflammation, intraocular pressure anomalies, or endophthalmitis were observed with a median follow-up of 18 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In the absence of controlled studies, this case series supports the use of intravitreal bevacizumab-bvzr as an anti-vascular endothelial growth factor therapy option, including in the pediatric population and resource-poor settings.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                [\n                <jats:italic>Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n                2023;54:84\u201388.]\n              <\/jats:bold>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/23258160-20230130-01","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T21:23:58Z","timestamp":1676323438000},"page":"84-88","source":"Crossref","is-referenced-by-count":7,"title":["Initial Experience With Biosimilar Bevacizumab-bvzr For Intravitreal Use in Children: A Case Series and Literature Review"],"prefix":"10.3928","volume":"54","author":[{"given":"Eric E.","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Nagiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S180393"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2016.1227783"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.3997"},{"key":"e_1_3_1_5_2","volume-title":"Biosimilar product regulatory review and approval","unstructured":"Biosimilar product regulatory review and approval. US Food and Drug Administration. Published 2017. Accessed March 13, 2022. https:\/\/www.fda.gov\/files\/drugs\/published\/Biosimilar-Product-Regulatory-Review-and-Approval.pdf"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.12.006"},{"issue":"4","key":"e_1_3_1_7_2","first-page":"3","article-title":"Biosimilar cost savings in the United States: initial experience and future potential","volume":"7","author":"Mulcahy AW","year":"2018","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3. PMID:30083415","journal-title":"Rand Health Q"},{"key":"e_1_3_1_8_2","volume-title":"Avastin shortages: academy, retina specialists ramp up efforts to address the issue","unstructured":"Avastin shortages: academy, retina specialists ramp up efforts to address the issue. American Academy of Ophthalmology. Published 2021. Accessed March 13, 2022. https:\/\/www.aao.org\/eye-on-advocacy-article\/avastin-shortages-academy-retina-specialists-ramp"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.5053"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00293-w"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00277-3"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S307746"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.031"},{"issue":"1","key":"e_1_3_1_14_2","first-page":"28","article-title":"Intraocular injection of stivant\u00ae (a biosimilar to bevacizumab): a case series","volume":"16","author":"Mirshahi A","year":"2021","unstructured":"Mirshahi A, Lashay A, Riazi-Esfahani H. Intraocular injection of stivant\u00ae (a biosimilar to bevacizumab): a case series. J Ophthalmic Vis Res. 2021;16(1):28\u201333. PMID:33520125","journal-title":"J Ophthalmic Vis Res"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.21474\/IJAR01\/6234"},{"key":"e_1_3_1_16_2","unstructured":"Changes to precertification requirements for intravitreal VEGF products effective January 1 2020. AmeriHealth . Published 2019. Accessed March 13 2022. https:\/\/provcomm.amerihealth.com\/ah\/archive\/pages\/c41b497b51d0587c8525848700667b93.aspx"},{"key":"e_1_3_1_17_2","volume-title":"Insurance companies are pushing biosimilar drugs that may damage vision","unstructured":"Insurance companies are pushing biosimilar drugs that may damage vision. American Academy of Ophthalmology. Published 2021. Accessed March 13, 2022. https:\/\/www.aao.org\/newsroom\/news-releases\/detail\/insurance-companies-are-pushing-biosimilar-drugs"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420930863"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2008.0098"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T04:31:33Z","timestamp":1683088293000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20230130-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.3928\/23258160-20230130-01"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20230130-01","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}